Introduction {#sec1_1}
============

Twenty-five members of a large family residing in the county of Devon in the southwest of England have been affected by atypical haemolytic uraemic syndrome (aHUS). This family was first described in 1978 by Edelsten and Tuck \[[@B1]\]. At that time, there were 4 affected individuals. Subsequently, in 1998, Warwicker et al. \[[@B2]\] established linkage to the regulators of complement activation (RCA) cluster of genes at chromosome 1q32 in 3 families including this one. One of the genes in this cluster is *CFH*, which encodes the soluble complement regulator factor H. In all the affected individuals (7 in total) from the Exeter region, Warwicker et al. \[[@B2]\] found a mutation in *CFH* (c.3643C\>G; p.Arg1215Gly). Since 1998, a further 18 individuals in this family have been affected and 18 unaffected carriers have been identified. The same mutation has also been identified in families residing in Wales and the Midlands. In both these families, there is strong evidence to suggest that they share a lineage in common with the family residing in the southwest of England. Since 1998, it has been shown that *CFH* mutations are the most frequent genetic abnormality in patients with aHUS, accounting for approximately 30% of cases \[[@B3]\]. The mutations are usually heterozygous and cluster in the C-terminal recognition domain of factor H \[[@B4]\]. Most result in a secreted mutant protein with impaired ability to regulate complement activation at cell surfaces. Progression to end-stage renal failure is rapid and recurrence rates after transplantation are high \[[@B5]\]. The mutations can present in childhood or adulthood with incomplete penetrance \[[@B6]\]. The high number of affected and unaffected individuals carrying *CFH* c.3643C\>G; p.Arg1215Gly in a family in a localised vicinity led us to examine whether other dialysis patients within the same vicinity might carry the same change and also whether the change might be detectable in the 'healthy' local population.

Methods and Results {#sec1_2}
===================

Case History {#sec2_1}
------------

In 2009, a 65-year-old male presented with malignant hypertension and acute kidney injury, having recently been started on an ACE inhibitor. A diagnosis of renovascular disease was made, and he did not recover renal function. He commenced regular haemodialysis and, 1 year later, received a live related kidney transplant from his son. Despite initial graft function, he rapidly lost the graft due to biopsy-proven thrombotic microangiopathy (TMA) (fig. [1](#F1){ref-type="fig"}). Subsequent mutation screening revealed that he carried *CFH* c.3643C\>G; p.Arg1215Gly without him being knowingly related to the local kindred. His son was found not to carry the mutation.

CFH Screening in Haemodialysis Patients {#sec2_2}
---------------------------------------

This case led us to examine the hypothesis that other patients undergoing haemodialysis in our unit might unknowingly carry this mutation. We reviewed the primary renal diagnoses of 294 haemodialysis patients in the Devon area. Using the inclusion/exclusion criteria shown in table [1](#T1){ref-type="table"}, we undertook *CFH* mutation screening in 7 patients as described previously \[[@B7]\]. Clinical information for these patients is given in table [2](#T2){ref-type="table"}. None of them were found to carry *CFH* c.3643C\>G; p.Arg1215Gly.

Prevalence of CFH c.3643C\>G; p.Arg1215Gly in the Local Population {#sec2_3}
------------------------------------------------------------------

This case also led us to examine the hypothesis that *CFH* c.3643C\>G; p.Arg1215Gly is endemic in the local population. We used the Exeter Ten Thousand (EXTEND; [www.exeter10000.org](http://www.exeter10000.org)) study to address this hypothesis. This study aims to recruit 10,000 healthy volunteers over the age of 18 years living within 25 miles of Exeter (the principle town in the vicinity of the family). To date, 4,000 individuals have entered the study. Each recruit consents for blood samples to be taken and used for a variety of purposes including genetic studies. The EXTEND steering committee approved access to 4,000 DNA samples for genotyping. None were found to carry *CFH* c.3643C\>G; p.Arg1215Gly.

Discussion {#sec1_3}
==========

In this study, we have examined whether haemodialysis patients within the same vicinity as the family initially described by Warwicker et al. \[[@B2]\] might unknowingly carry *CFH* c.3643C\>G; p.Arg1215Gly. This was pre-empted by the discovery of this change in a patient who developed post-transplant TMA, in whom the original underlying diagnosis was malignant hypertension. We specifically screened those haemodialysis patients without a primary diagnosis and those with a diagnosis of malignant hypertension or chronic glomerulonephritis (not biopsied) or renovascular disease. Seven patients met these criteria, and in none of them did we find *CFH* c.3643C\>G; p.Arg1215Gly. At the same time, we screened 4,000 healthy individuals living within the same vicinity as the family described by Warwicker et al. \[[@B2]\] for *CFH* c.3643C\>G; p.Arg1215Gly, and in none of them did we find this change.

Although we have not been able to categorically show that the index patient shares a common lineage to the family described by Warwicker et al. \[[@B2]\], we assume this to be the case. Le Quintrec et al. \[[@B8]\] have previously shown that 29% of patients with de novo post-transplant TMA have a mutation in either *CFH* and/or *CFI*. Based on this observation, it is routine practice within the UK to screen all patients with de novo post-transplant TMA for mutations in *CFH*, *CFI*, *CD46*, *C3* and *CFB*, and to screen for factor H autoantibodies. This practice led to the finding of *CFH* c.3643C\>G; p.Arg1215Gly in this patient. It is interesting that his primary renal diagnosis was malignant hypertension. Both the presentation of malignant hypertension and the renal biopsy findings in this condition can be similar to aHUS. It is unfortunate that at the time of his presentation eculizumab was not available. There is now overwhelming evidence that recurrent post-transplant aHUS responds to treatment with eculizumab \[[@B9]\]. Both the findings of Le Quintrec et al. \[[@B8]\] and the observation that this patient presented with apparent de novo post-transplant TMA raise the possibility that de novo post-transplant TMA should be treated with eculizumab especially if it is resistant to plasma exchange. There are anecdotal reports supporting this \[[@B10],[@B11]\]. Future transplantation in this patient will undoubtedly need to be undertaken under the cover of eculizumab.

The case we report here and the large number of affected/unaffected carriers of *CFH* c.3643C\>G; p.Arg1215Gly in the family described by Warwicker et al. \[[@B2]\] also led us to examine whether this sequence variant might be detectable within the 'healthy' population in the vicinity of this family. We screened 4,000 such individuals and did not find this variant. This is in keeping with the absence of the change in any other haemodialysis patients in the region.

Despite not finding this change in either the haemodialysis population or the local healthy population, we have a low index of suspicion for undertaking mutation screening in those patients who present with features such as malignant hypertension that might be compatible with a diagnosis of aHUS.
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![Progressive TMA changes over subsequent renal transplant biopsies. **A** A relatively 'bloodless' glomerulus containing small hilar thrombi in the first biopsy. **B** Second biopsy with the glomerulus (long arrow) showing segmental thrombosis and subtle erythrocyte fragmentation. An arteriole cut longitudinally (short arrow) shows endothelial cell swelling and intimal expansion by myxoid/fibrinoid-necrotic material. **C** Second biopsy with the arteriole (long arrow) showing luminal obliteration by fibro-myxoid intimal thickening and erythrocyte extravasation and fragmentation. The arteriole (short arrow) shows a swollen endothelium and marked myxoid subendothelial thickening, compromising the lumen. **D** Third biopsy showing chronic TMA changes in the form of a 'glomeruloid body' (arrow) produced by proliferating endothelial cells, myocytes and myofibroblasts within an arteriole/small interlobular artery in response to injury, and prominent ischaemic glomerular and tubulointerstitial changes.](nne-0003-0086-g01){#F1}

###### 

Inclusion and exclusion criteria for haemodialysis patients

  -------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Inclusion criteria   Diagnoses of malignant hypertension, unknown aetiology, chronic glomerulonephritis (never biopsied) or renovascular disease 3 generations from Devon
                       
  Exclusion criteria   Another biopsy-proven diagnosis, adult polycystic kidney disease, nephrectomy, obstructive uropathy, diabetes, reflux nephropathy, drug-related causes Patient moved to Devon
  -------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

###### 

Haemodialysis patients tested for CFH c.3643C\>G; p.Arg1215Gly mutation

  Patient   Age   Diagnosis                  Renal biopsy        Ultrasound                             Hb     Platelets   LDH   Blood film
  --------- ----- -------------------------- ------------------- -------------------------------------- ------ ----------- ----- ---------------------------
  1         76    Unknown                    No                  Small kidneys                          8.4    243               
  2         54    Hypertensive nephropathy   No                  L 10.2 cm                              7.4    337         638   
                                                                 R 10.7 cm, simple cyst at upper pole                            
  3         71    Hypertensive nephropathy   Inconclusive        L 10.9 cm, small cortical cyst         14.6   294               
                                                                 R 10.4 cm                                                       
  4         78    Renovascular disease       Ischaemic changes                                          12.8   238               
  5         36    Hypertensive nephropathy   No                                                         15.7   196               Occasional platelet clump
  6         73    Renovascular disease       No                  L 11.6 cm                              13.6   168               
                                                                 R 9.3 cm                                                        
  7         79    Hypertensive nephropathy   No                  L 8.5 cm, numerous small cysts         11.7   291               
                                                                 R 8.7 cm, numerous small cysts                                  
